RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.1
You are now leaving the AbbVie Pro Portal and being re-directed to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
Reporting of side effects (patients and public in the UK)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.
For medicines with black triangle: ▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.